Literature DB >> 20136683

Cognitive profile in a large French cohort of adults with Prader-Willi syndrome: differences between genotypes.

P Copet1, J Jauregi, V Laurier, V Ehlinger, C Arnaud, A-M Cobo, C Molinas, M Tauber, D Thuilleaux.   

Abstract

BACKGROUND: Prader-Willi syndrome (PWS) is a rare genetic disorder characterised by developmental abnormalities leading to somatic and psychological symptoms. These include dysmorphic features, impaired growth and sexual maturation, hyperphagia, intellectual delay, learning disabilities and maladaptive behaviours. PWS is caused by a lack of expression of maternally imprinted genes situated in the 15q11-13 chromosome region. The origin is a 'de novo' deletion in the paternal chromosome in 70% of the cases and a maternal uniparental disomy in 25%. The two main genotypes show differences, notably regarding cognitive and behavioural features, but the mechanisms are not clear. This study assessed cognitive impairment in a cohort of adults with genetically confirmed PWS, analysed their profiles of cognitive strengths and weaknesses, and compared the profiles in terms of genotype.
METHODS: Ninety-nine male and female adults participated, all inpatients on a specialised unit for the multidisciplinary care of PWS. The Wechsler Adult Intelligence Scale (WAIS-III) was administered to all patients in identical conditions by the same psychologist. Eighty-five patients were able to cope with the test situation. Their scores were analysed with non-parametric statistical tools. The correlations with sex, age and body mass index were explored. Two genotype groups were compared: deletion (n = 57) and non-deletion (n = 27).
RESULTS: The distribution of intelligence quotients in the total cohort was non-normal, with the following values (medians): Full Scale Intelligence Quotient (FSIQ): 52.0 (Q1:46.0; Q3:60.0), Verbal Intellectual Quotient (VIQ): 53.0 (Q1:48; Q3:62) and Performance Intellectual Quotient (PIQ): 52.5 (Q1:48; Q3:61). No correlation was found with sex, age or body mass index. Comparison between groups showed no significant difference in FSIQ or VIQ. PIQ scores were significantly better in the deletion group. The total cohort and the deletion group showed the VIQ = PIQ profile, whereas VIQ > PIQ was observed in the non-deletion group. The subtest scores in the two groups showed significant differences, with the deletion group scoring better in three subtests: object assembly, picture arrangement and digit symbol coding. Some relative strengths and weaknesses concerned the total cohort, but others concerned only one genotype. DISCUSSION: We documented a global impairment in the intellectual abilities of a large sample of French PWS patients. The scores were slightly lower than those reported in most other studies. Our data confirmed the previously published differences in the cognitive profiles of the two main PWS genotypes and offer new evidence to support this hypothesis. These results could guide future neuropsychological studies to determine the cognitive processing in PWS. This knowledge is essential to improve our understanding of gene-brain-behaviour relationships and to open new perspectives on therapeutic and educational programmes.

Entities:  

Mesh:

Year:  2010        PMID: 20136683     DOI: 10.1111/j.1365-2788.2010.01251.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  21 in total

1.  Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients.

Authors:  Maïthe Tauber; Carine Mantoulan; Pierre Copet; Joseba Jauregui; Genevieve Demeer; Gwenaëlle Diene; Bernadette Rogé; Virginie Laurier; Virginie Ehlinger; Catherine Arnaud; Catherine Molinas; Denise Thuilleaux
Journal:  Orphanet J Rare Dis       Date:  2011-06-24       Impact factor: 4.123

Review 2.  Prader-Willi syndrome and early-onset morbid obesity NIH rare disease consortium: A review of natural history study.

Authors:  Merlin G Butler; Virginia Kimonis; Elisabeth Dykens; June A Gold; Jennifer Miller; Roy Tamura; Daniel J Driscoll
Journal:  Am J Med Genet A       Date:  2017-12-22       Impact factor: 2.802

Review 3.  Neuroanatomical and molecular correlates of cognitive and behavioural outcomes in hypogonadal males.

Authors:  O B Akinola; M O Gabriel
Journal:  Metab Brain Dis       Date:  2017-12-11       Impact factor: 3.584

4.  Early Detection and Management of Prader-Willi Syndrome in Egyptian Patients.

Authors:  Hala T El-Bassyouni; Nagwa Hassan; Inas Mahfouz; Azza E Abd-Elnaby; Mostafa I Mostafa; Angie M S Tosson
Journal:  J Pediatr Genet       Date:  2019-08-04

5.  Discrepancies between fluid and crystallized ability in healthy adults: a behavioral marker of preclinical Alzheimer's disease.

Authors:  Ian M McDonough; Gérard N Bischof; Kristen M Kennedy; Karen M Rodrigue; Michelle E Farrell; Denise C Park
Journal:  Neurobiol Aging       Date:  2016-06-25       Impact factor: 4.673

6.  Using IQ discrepancy scores to examine the neural correlates of specific cognitive abilities.

Authors:  Amy Margolis; Ravi Bansal; Xuejun Hao; Molly Algermissen; Cole Erickson; Kristin W Klahr; Jack A Naglieri; Bradley S Peterson
Journal:  J Neurosci       Date:  2013-08-28       Impact factor: 6.167

7.  Prader-Willi syndrome: A primer for clinicians.

Authors:  Mary Cataletto; Moris Angulo; Gila Hertz; Barbara Whitman
Journal:  Int J Pediatr Endocrinol       Date:  2011-10-18

Review 8.  A cross-comparison of cognitive ability across 8 genomic disorders.

Authors:  Michael Mortillo; Jennifer G Mulle
Journal:  Curr Opin Genet Dev       Date:  2021-05-31       Impact factor: 4.665

9.  Social and emotional processing in Prader-Willi syndrome: genetic subtype differences.

Authors:  Alexandra P Key; Dorita Jones; Elisabeth M Dykens
Journal:  J Neurodev Disord       Date:  2013-03-27       Impact factor: 4.025

10.  Behavioral profile of adults with Prader-Willi syndrome: correlations with individual and environmental variables.

Authors:  Joseba Jauregi; Virginie Laurier; Pierre Copet; Maithé Tauber; Denise Thuilleaux
Journal:  J Neurodev Disord       Date:  2013-08-06       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.